Skip to main content
Erschienen in: International Journal of Colorectal Disease 5/2010

01.05.2010 | Original Article

Role of TGF-β1, its receptor TGFβRII, and Smad proteins in the progression of colorectal cancer

verfasst von: Maya Gulubova, Irena Manolova, Julian Ananiev, Alexander Julianov, Yovcho Yovchev, Katya Peeva

Erschienen in: International Journal of Colorectal Disease | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim

In the current study, we investigated the expression of TGF-β1, its receptor TGFβRII, and the signaling proteins Smad4 and Smad7 in colorectal cancer tissue in relation to infiltration with antigen-presenting cells and some clinical and pathologic parameters of disease progression in patients with colorectal cancer (CRC).

Materials and methods

The immunohistochemical expression of TGF-β1, TGFβRII, Smad4, Smad7, HLA-DR antigen, CD1a, CD83, and CD68 was evaluated in 142 patients (50 females and 92 males) with CRC, followed-up for 6–8 years period.

Results

In our study, 127 (89.4%) out of 142 colorectal cancers displayed cytoplasmic TGF-β1 immunoreactivity. Common-mediator Smad4 was detected in the tumor cytoplasm in 124 cancers (79.5%) and inhibitory Smad7 immunostaining was observed in 110 (77.4%) tumor specimens. TGFβRII was expressed on tumor cell membranes in 119 (76.3%) of the cancers. The increased TGF-β1 expression in tumor cytoplasm was related to low CD68+- and CD83+-cell infiltration in tumor tissues. Patients with TGF-β1 overexpression had worse prognosis after surgical therapy compared to those with low expression of TGF-β1. The observed association was more pronounced for the patients in T1–T2 stage (p = 0.0015).

Conclusions

The expression of TGF-β1, its receptor TGFβRII, and signaling proteins Smad4 and Smad7 was observed in the majority of colorectal cancer specimens. Our results suggest that TGF-β1 production by tumor cells may affect the tumor environment via suppression of tumor-infiltrating immune cells and probably contributes to tumor cells aggressiveness through autocrine activation of Smad signaling.
Literatur
1.
Zurück zum Zitat Baker K, Chong G, Foulkes WD, Jass JR (2006) Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology 49:371–380CrossRefPubMed Baker K, Chong G, Foulkes WD, Jass JR (2006) Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology 49:371–380CrossRefPubMed
2.
Zurück zum Zitat Korchynskyi O, Landstrom M, Stoika R, Funa K, Heldin C-H, ten Dijke P, Souchelnytskyi S (1999) Expression of Smad proteins in human colorectal cancer. Int J Cancer 82:197–202CrossRefPubMed Korchynskyi O, Landstrom M, Stoika R, Funa K, Heldin C-H, ten Dijke P, Souchelnytskyi S (1999) Expression of Smad proteins in human colorectal cancer. Int J Cancer 82:197–202CrossRefPubMed
3.
Zurück zum Zitat Elliot RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093CrossRef Elliot RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093CrossRef
4.
Zurück zum Zitat Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A (2007) TGF-beta receptor downregulation in tumor-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7:156–166CrossRefPubMed Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A (2007) TGF-beta receptor downregulation in tumor-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7:156–166CrossRefPubMed
5.
Zurück zum Zitat Xu Y, Pashe B (2007) TGF-β signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 16(SPEC1):R14-R20. doi:10.1093/hmg/dd1486 Xu Y, Pashe B (2007) TGF-β signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 16(SPEC1):R14-R20. doi:10.​1093/​hmg/​dd1486
6.
Zurück zum Zitat Heldin C-H, Miyazono K, ten Duke P (1997) TGF- β signaling from cell membrane to nucleus via Smad proteins. Nature 390:465–471CrossRefPubMed Heldin C-H, Miyazono K, ten Duke P (1997) TGF- β signaling from cell membrane to nucleus via Smad proteins. Nature 390:465–471CrossRefPubMed
7.
Zurück zum Zitat Derynck R, Feng X-H (1997) TGF- β receptor signaling. Biochim Biophys Acta 1333:F105–F150PubMed Derynck R, Feng X-H (1997) TGF- β receptor signaling. Biochim Biophys Acta 1333:F105–F150PubMed
8.
Zurück zum Zitat Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T (1999) Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59:3379–3386PubMed Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T (1999) Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59:3379–3386PubMed
9.
Zurück zum Zitat Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A (1995) High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4:549–554PubMed Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A (1995) High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4:549–554PubMed
10.
Zurück zum Zitat Robson H, Anderson E, James RD, Schofield PF (1996) Transforming growth factor beta 1 expression in human colorectal tumors: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74:753–758PubMed Robson H, Anderson E, James RD, Schofield PF (1996) Transforming growth factor beta 1 expression in human colorectal tumors: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74:753–758PubMed
11.
Zurück zum Zitat Shibahara T, Si-Tahar M, Shaw SK, Madara JL (2000) Adhesion molecules expressed on homing lymphocytes in model intestinal epithelia. Gastroenterology 118:289–298CrossRefPubMed Shibahara T, Si-Tahar M, Shaw SK, Madara JL (2000) Adhesion molecules expressed on homing lymphocytes in model intestinal epithelia. Gastroenterology 118:289–298CrossRefPubMed
12.
Zurück zum Zitat Reinacher-Schick A, Baldus SE, Romdhana B, Landsberg S, Zapatka M, Monig SP, Holscher AH, Dienes HP, Schmiegel W, Schwarte-Waldhoff I (2004) Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas. J Pathol 202:412–420CrossRefPubMed Reinacher-Schick A, Baldus SE, Romdhana B, Landsberg S, Zapatka M, Monig SP, Holscher AH, Dienes HP, Schmiegel W, Schwarte-Waldhoff I (2004) Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas. J Pathol 202:412–420CrossRefPubMed
13.
Zurück zum Zitat Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365–370PubMedCrossRef Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365–370PubMedCrossRef
14.
Zurück zum Zitat Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metast Rev 26:373–400CrossRef Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metast Rev 26:373–400CrossRef
15.
Zurück zum Zitat NakayamaY NN, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, Sako T, Hirata K, Nagata N, Itoh H (2002) Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 22:4291–4296 NakayamaY NN, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, Sako T, Hirata K, Nagata N, Itoh H (2002) Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 22:4291–4296
16.
Zurück zum Zitat Shurin MR, Shurin GV, Lokshin A, Yurkovetsky Z, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL (2006) Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25:333–356CrossRefPubMed Shurin MR, Shurin GV, Lokshin A, Yurkovetsky Z, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL (2006) Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25:333–356CrossRefPubMed
17.
Zurück zum Zitat Miygawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T (2004) Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 35:1392–1396CrossRef Miygawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T (2004) Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 35:1392–1396CrossRef
18.
Zurück zum Zitat Gulubova М, Manolova I, Cirovski G, Sivrev D (2008) Recruitment of dendritic cells in human liver with metastases. Clin Exp Metast 25:777–785CrossRef Gulubova М, Manolova I, Cirovski G, Sivrev D (2008) Recruitment of dendritic cells in human liver with metastases. Clin Exp Metast 25:777–785CrossRef
19.
Zurück zum Zitat UICC. TNM Classification of Malignant Tumours 6th ed (2002) In: Sobin LH, Wittekind Ch (eds) Wiley-Liss, New York UICC. TNM Classification of Malignant Tumours 6th ed (2002) In: Sobin LH, Wittekind Ch (eds) Wiley-Liss, New York
20.
Zurück zum Zitat Kioshima T, Kobayashi I, Matsuo K, Ishibashi Y, Miyoshi A, Akashi Y, Sakai H (1998) Immunohistochemical localization of laminin, collagen type IV and heparan sulfate proteoglycan in human colorectal adenocarcinoma: correlation with local invasive pattern and lymph node metastasis. Acta Histochem Cytochem 31:39–47 Kioshima T, Kobayashi I, Matsuo K, Ishibashi Y, Miyoshi A, Akashi Y, Sakai H (1998) Immunohistochemical localization of laminin, collagen type IV and heparan sulfate proteoglycan in human colorectal adenocarcinoma: correlation with local invasive pattern and lymph node metastasis. Acta Histochem Cytochem 31:39–47
21.
Zurück zum Zitat Gulubova M, Vlaykova T (2006) Immunohistochemical assessment of fibronectin and tenascin and their integrin receptors alpha5beta1 and alpha9beta1 in gastric and colorectal cancers with lymph node and liver metastases. Acta Histochem 108:25–35CrossRefPubMed Gulubova M, Vlaykova T (2006) Immunohistochemical assessment of fibronectin and tenascin and their integrin receptors alpha5beta1 and alpha9beta1 in gastric and colorectal cancers with lymph node and liver metastases. Acta Histochem 108:25–35CrossRefPubMed
22.
Zurück zum Zitat Guzinska-Ustymowicz K, Kemona A (2005) Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol 11:1193–1195PubMed Guzinska-Ustymowicz K, Kemona A (2005) Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol 11:1193–1195PubMed
23.
Zurück zum Zitat Von Rahden BHA, Stein HJ, Feith M, Puhringer F, Theisen J, Siewert R, Sarbia M (2006) Overexpression of TGF-β1 in esophageal (Barrett’s) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 45:786–794CrossRef Von Rahden BHA, Stein HJ, Feith M, Puhringer F, Theisen J, Siewert R, Sarbia M (2006) Overexpression of TGF-β1 in esophageal (Barrett’s) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 45:786–794CrossRef
24.
Zurück zum Zitat Lu Y, Wu L-Q, Li C-S, Wang S-G, Han B (2008) Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int 7:174–178PubMed Lu Y, Wu L-Q, Li C-S, Wang S-G, Han B (2008) Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int 7:174–178PubMed
25.
Zurück zum Zitat Park YN, Chae KJ, Oh B-K, Choi J, Choi KS, Park C (2004) Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-β. Hepato-Gastroenterol 51:396–400 Park YN, Chae KJ, Oh B-K, Choi J, Choi KS, Park C (2004) Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-β. Hepato-Gastroenterol 51:396–400
26.
Zurück zum Zitat Picon A, Gold LI, Wang J, Cohen A, Friedman E (1998) A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor β1. Cancer Epidemiol Biomark Prev 7:497–504 Picon A, Gold LI, Wang J, Cohen A, Friedman E (1998) A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor β1. Cancer Epidemiol Biomark Prev 7:497–504
27.
Zurück zum Zitat Chang H-L, Gillett N, Figari I, Lopez A, Palladino M, Derynck R (1993) Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53:4391–4398PubMed Chang H-L, Gillett N, Figari I, Lopez A, Palladino M, Derynck R (1993) Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53:4391–4398PubMed
28.
Zurück zum Zitat Shim KS, Kim KH, Han WS, Park EB (1999) Elevated serum levels of transforming growth factor- β1 in patients with colorectal carcinoma. Cancer 85:554–561CrossRefPubMed Shim KS, Kim KH, Han WS, Park EB (1999) Elevated serum levels of transforming growth factor- β1 in patients with colorectal carcinoma. Cancer 85:554–561CrossRefPubMed
29.
Zurück zum Zitat Gold L, Saxena B, Mittalk K, Marmor M, Goswami S, Nactigal L, Kork M, Demopoulos R (1994) Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 54:2347–2358PubMed Gold L, Saxena B, Mittalk K, Marmor M, Goswami S, Nactigal L, Kork M, Demopoulos R (1994) Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 54:2347–2358PubMed
30.
Zurück zum Zitat Gorsch S, Memoli V, Stukel T, Gold L, Arrick B (1992) Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 52:6949–6952PubMed Gorsch S, Memoli V, Stukel T, Gold L, Arrick B (1992) Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 52:6949–6952PubMed
31.
Zurück zum Zitat Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G, Emanuelli G, Rodeck U (2001) Differential expression of transforming growth factors- β1, -β2 and -β3 in human colon carcinoma. Eur J Cancer 37:224–233CrossRefPubMed Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G, Emanuelli G, Rodeck U (2001) Differential expression of transforming growth factors- β1, -β2 and -β3 in human colon carcinoma. Eur J Cancer 37:224–233CrossRefPubMed
32.
Zurück zum Zitat Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin J-P, Hemminki A, Schwartz S, Aaltonen L, Arango D (2005) Smad4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11:2606–2611CrossRefPubMed Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin J-P, Hemminki A, Schwartz S, Aaltonen L, Arango D (2005) Smad4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11:2606–2611CrossRefPubMed
33.
Zurück zum Zitat Isaksson-Mettavainio M, Palmqvist R, Forssell J, Stenling R, Oberg A (2006) Smad4/DPC4 expression and prognosis in human colorectal cancer. Anticancer 26:507–510 Isaksson-Mettavainio M, Palmqvist R, Forssell J, Stenling R, Oberg A (2006) Smad4/DPC4 expression and prognosis in human colorectal cancer. Anticancer 26:507–510
34.
Zurück zum Zitat Javelaud D, Delmas V, Moller M, Sextius P, Andre J, Menashi S, Larue L, Mauviel A (2005) Stable verexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 24:7624–7629CrossRefPubMed Javelaud D, Delmas V, Moller M, Sextius P, Andre J, Menashi S, Larue L, Mauviel A (2005) Stable verexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 24:7624–7629CrossRefPubMed
35.
Zurück zum Zitat Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336–1338CrossRefPubMed Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336–1338CrossRefPubMed
Metadaten
Titel
Role of TGF-β1, its receptor TGFβRII, and Smad proteins in the progression of colorectal cancer
verfasst von
Maya Gulubova
Irena Manolova
Julian Ananiev
Alexander Julianov
Yovcho Yovchev
Katya Peeva
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 5/2010
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-010-0906-9

Weitere Artikel der Ausgabe 5/2010

International Journal of Colorectal Disease 5/2010 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.